Skip to content

WelZCaVa ? wellbeing registry for pregnant women with cardiovascular disease

Development of a registry of clinical, patient-reported outcomes and experiences for pregnant women with cardiovascular conditions

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ISRCTN
Registry ID
ISRCTN12003030
Enrollment
75
Registered
2024-11-19
Start date
2023-09-10
Completion date
Unknown
Last updated
2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Female patients who are currently pregnant and being followed for congenital, hereditary or acquired cardiovascular disease Circulatory System

Interventions

Data are collected using the medical/electronic patient record and a set of questionnaires covering the selected PROMS and PREMS. The registry will collect data from the first consultation at a terti

Sponsors

University of Antwerp
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1. Ongoing follow-up at the cardio-obstetrics/heart and women service at one of the participating centres 2. Pregnant women with congenital heart disease as defined by Mitchell et al, 1971; and/or acquired heart disease; and/or severe pre-existing hypertension; and/or cardiac arrhythmias (with or without the presence of an internal defibrillator); and/or a history of peripartum cardiomyopathy; and/or systemic diseases with cardiac burden.

Exclusion criteria

Exclusion criteria: 1. Pregnant women with pre-eclampsia/HELLP (haemolysis, elevated liver enzymes and low platelets) as a primary cardiovascular condition

Design outcomes

Primary

MeasureTime frame
Patient-reported outcomes: 1. The possible presence of depressive symptoms is measured using the validated Whooley scale 2. The possible presence of an anxiety disorder is measured using the General Anxiety Disorder 7 questionnaire 3. Autonomy and shared decision-making are assessed using the Mothers on Autonomous Decision Making (MADM) scale 4. Social support is measured using the validated Oslo-3 scale 5. Empowerment is assessed using the validated Pregnancy Related Empowerment Scale (PRES) 6. Symptoms of possible (postnatal) depression, anxiety and suicidal ideation assessed using the Edinburgh Postnatal Depression Scale (EPDS) 7. Mother-infant bonding is assessed using the Mother-Infant Bonding Scale (MIBS). The validated Postpartum Bonding Questionnaire (PBQ) is also administered at the same time to ensure that mother-child bonding has been properly assessed. Patient-reported experiences: Patient satisfaction will be measured using the validated Maternity Satisfaction with Care Questionnaire (MSCQ) developed as part of the Born in Belgium study. The registry will collect these data from the first consultation in a tertiary centre up to and including 12 weeks after delivery (cf. fourth trimester). For each enrolled pregnant woman, there will be at least 4 data collection points: at least 1 data collection point during the perinatal period, depending on the date of enrolment and the current gestational age (cf. trimester 1, 2 or 3) and at least 3 data collection points during the postpartum period (cf. week 1, 6 and 12 postpartum). Figure 1 of the study protocol provides a visual overview of the respective data collection points for demographics and clinical outcomes. Figure 2 also provides a visual overview of the respective data collection points for the PROMS and PREMS datasets. It is important to note that the date of enrolment during the perinatal period is a highly variable element of the study, where the date of the patient's first registration at the

Secondary

MeasureTime frame
The following set of obstetric, maternal and fetal/neonatal outcomes will be collected from the medical record once at 2 weeks postpartum: 1. The set of maternal and obstetric outcomes listed in Appendix 2 of the study protocol will consist of the following variables: maternal mortality, length of stay, haemorrhage; obstetric outcomes such as abruptio placentae, haemorrhage, emergency caesarean section, rupture of membranes (ROM); left ventricular ejection fraction, cardiomyopathy (CMP), arrhythmia, pulmonary hypertension, thromboembolic complications; hypertension, endocarditis and cardiomyopathy. 2. The set of fetal/neonatal outcomes listed in Appendix 3 of the protocol will consist of the following data: APGAR score, birth weight, length of stay, fetal mortality, reason for preterm birth, neonatal admission, neonatal mortality, intrauterine growth restriction (IUGR) and birth injury. The registry will collect these data from the first consultation in a tertiary centre up to and including 12 weeks after delivery (cf. fourth trimester). For each enrolled pregnant woman, there will be at least 4 data collection points: at least 1 data collection point during the perinatal period, depending on the date of enrolment and the current gestational age (cf. trimester 1, 2 or 3) and at least 3 data collection points during the postpartum period (cf. week 1, 6 and 12 postpartum). Figure 1 of the study protocol provides a visual overview of the respective data collection points for demographics and clinical outcomes. Figure 2 also provides a visual overview of the respective data collection points for the PROMS and PREMS datasets. It is important to note that the date of enrolment during the perinatal period is a highly variable element of the study, where the date of the patient's first registration at the outpatient clinic may vary between trimester 1, 2 or 3. During this perinatal period there will be at least one measurement time per participating patient. However, depe

Countries

Belgium

Contacts

Public ContactYaël Vanharen
yael.vanharen@uantwerp.be+324 70 37 96 90

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026